Clinical Trials Logo

Clinical Trial Summary

The investigators have designed a 2-center, pilot feasibility, randomized controlled trial (PROXIMUS) to determine the feasibility and safety of a larger multi center, randomized open-label trial comparing high protein combined with individualized exercise vs. standard management during the acute phase of critical illness in children. The investigators aim to determine the impact of the intervention on preservation of muscle mass; and functional status at 1 month and 6 months after randomization.


Clinical Trial Description

Mortality in U.S. pediatric intensive care units (PICUs) is improving, resulting in an increased focus on the quality of life of survivors who often have persistent physical, cognitive, and psychological impairments. Mechanically ventilated children in particular experience immobilization and poor nutrient intake, which results in muscle loss during acute illness. Early mobility and optimal nutrition during acute critical illness have been associated with muscle mass preservation and decreased duration of mechanical ventilation. These interventions may have the potential to decrease preventable PICU-acquired morbidities. However, the optimal doses and long-term benefits of these interventions have not been shown in randomized studies of critically ill PICU patients. Thus, the investigators will test the first pediatric-specific, inter-professional intervention that integrates high protein and individualized exercise. This intervention was developed by a team of experts in the fields of nutrition, early mobility, rehabilitative exercise, muscle ultrasound (US), and functional outcomes. The investigators propose a 2-center, pilot feasibility, randomized controlled trial (PROXIMUS) with the following Specific Aims: 1. To determine the feasibility and safety of a randomized open-label trial comparing high protein combined with individualized exercise vs. standard management during the acute phase of critical illness in children; 2. To determine the impact of high protein and individualized exercise on preservation of muscle mass; and 3. To determine the impact of high protein and individualized exercise on functional status at 1 month and 6 months after randomization. Outcomes: The investigators will assess feasibility with a composite measure that combines predetermined thresholds for screening, enrollment, allocation, and compliance/adherence with significant separation in doses of protein and exercise between the two arms. Safety will be defined as absence of difference in rates of new renal injury and exercise related adverse events. Preservation of muscle mass will be assessed by percent daily change in US-measured quadriceps femoris muscle thickness (QFMT) during the PICU stay. The investigators will use a validated imaging protocol with high reliability and reproducibility. The investigators will also examine the difference in the normative standard scores (T-scores) between the two arms for the Pediatric Evaluation of Disability Inventory - Computer Adaptive Test (PEDI-CAT) assessment. Other secondary outcomes are Functional Status Scale, PedsQL, and muscle quality by US. The investigators hypothesize that a larger trial will be feasible and safe. Patients randomized to the combined intervention will have lower decline in QFMT and better scores on PEDI-CAT assessment. If proven feasible and safe, the PROXIMUS intervention has potential to profoundly change medical care in the PICU and substantially impact public health by improving long-term outcomes for the growing number of pediatric survivors of critical illness. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05296096
Study type Interventional
Source Boston Children's Hospital
Contact Nilesh M. Mehta, MD
Phone 6173557327
Email nilesh.mehta@childrens.harvard.edu
Status Recruiting
Phase N/A
Start date February 20, 2023
Completion date June 30, 2026

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05818644 - Hepatic Artery Stenosis and Thrombosis After Liver Transplantation in Children
Not yet recruiting NCT06018324 - CloudCare in the Treatment of Type 1 Diabetes in Pediatrics
Not yet recruiting NCT04523623 - Pain Control Differences Between Oxycodone and Ibuprofen in Children With Isolated Forearm Injuries N/A
Completed NCT02930850 - Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation N/A
Completed NCT03385681 - Pediatric Pain Management - an Intervention Study N/A
Completed NCT00229671 - Medication Errors and Adverse Drug Events (ADEs) in Ambulatory Pediatrics N/A
Completed NCT04465370 - Pediatric Cardiac Output Monitoring Observational Study
Recruiting NCT04100070 - Intensive Versus Standard One Year Monitoring on Glycaemic Control After Initiating CSII in Children With DT1. DEEP Study N/A
Not yet recruiting NCT06035757 - The Occurrence of Emergence Agitation in Pediatric Strabismus Surgery Phase 4
Completed NCT03369847 - Inhaled Steroids for Pediatric Asthma at Pediatric Emergency Medicine Discharge Phase 4
Completed NCT05474170 - Impact of 2 Resuscitation Sequences on Management of Simulated Pediatric Cardiac Arrest N/A
Recruiting NCT05230004 - Innovative Prosthetic Systems for Pediatric Limb Loss to Accommodate Growth N/A
Completed NCT05818215 - Impact of the Qatar 2022 FIFA World Cup on PED Use and Misuse Patterns
Completed NCT06376188 - Improving Breaking Bad News in Pediatrics by Simulated Communication N/A
Completed NCT05731401 - Expressed Beliefs About the Cause of Pain in a Paediatric Population
Completed NCT04589910 - Measuring Thickness of the Normal Diaphragm in Children Via Ultrasound. N/A
Recruiting NCT04252508 - Impact of a Double-reading Animated Film (Child, Parents) in Preoperative on the Anxiety of Children Upon Arrival at the Operating Room N/A
Completed NCT04655378 - Validation of the IgA1 Detection Method With Gradient Glycosylation by Mass Spectrometry as a Potential Marker of Renal Involvement in Pediatric Rheumatoid Purpura
Completed NCT04610918 - Comparing Body Composition Assessment Methods
Completed NCT03964259 - Reduced IV Fluids to Improve Clearance of HDMTX in Children w/Lymphoma or Acute Lymphoblastic Leukemia Phase 1